• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

New treatment target for paclitaxel-induced pain [PreClinical]

byCorinne FoleyandJessica Lau
December 19, 2016
in Chronic Disease, Oncology, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In mouse models, the lipid metabolite 9,10 EpOME was identified as an important mediator of paclitaxel-induced peripheral neuropathic pain (PIPN).

2. Following the inhibition of the upstream lipid oxygenase CYP2J with drug, levels of 9,10 EpOME were reduced and PIPN was significantly reduced as well.

Evidence Rating Level: 2 (Good)

Study Rundown: Paclitaxel is currently the first line therapy for breast cancer; however, a main side effect of this therapy is peripheral neuropathy. This side effect involves pain in the extremities without a painful stimulus. The goal of this study was to determine the mechanism through which PIPN is induced, in order to identify a treatment that could lead to the alleviation of the pain experienced by patients.

Using dorsal root ganglia cells from mice, the levels of lipid metabolites were measured following paclitaxel administration. The levels of a linoleic acid metabolite, 9,10-EpOME, were elevated in the mice. This metabolite was found to increase the frequency of nerve firing and reduce the pain threshold of mice. Correspondingly, the expression of CYP2J, the lipid oxygenase that synthesizes 9,10 EpOME, was increased in these mice. When CYP2J was inhibited with the drugs telmisartan or terfenadine, the production of 9,10-EpOME was diminished and led to decreased sensitivity to both mechanical and thermal stimuli.

The researchers in this study were able to elucidate the mechanism through which paclitaxel induces peripheral neuropathy, allowing for the discovery of a novel treatment for this debilitating side effect. Although future studies will need to determine the efficacy of this treatment in humans as well as the benefit that it truly has on pain levels, it provides a promising option towards alleviating pain in patients taking paclitaxel.

Click to read the study in PNAS

RELATED REPORTS

#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers

#VisualAbstract: Metformin does not improve survival in patients with high-risk, nonmetastatic breast cancer

#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage

Relevant Reading: Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis

In-Depth [animal study]: Varying doses of paclitaxel were administered to mice and nervous system components were extracted after 8 days. Liquid chromatography-mass spectroscopy was then used to look for altered levels of lipid metabolites. A lineoleic acid derivative, 9,10-EpOME, was found to be the only lipid elevated in the mice that received paclitaxel (p<0.05).

The effect of this metabolite on neuronal firing was then assessed. Patch clamp recorders were used to measure the spontaneous excitatory post synaptic potentials (sEPSCs) of spinal cord slices from mice following the administration of varying concentrations of 9,10-EpOME. Neuron firing was potentiated with the addition of capsaicin, a compound known to increase neuronal firing and induce pain. A concentration-dependent increase in firing was noted with 9,10-EpOME, supporting the hypothesis of its role in PIPN.

In an evaluation of lipid oxygenases, the levels of CYP2J expression were found to be elevated using qRT-PCR (p<0.01). CYP2J was determined to be most likely involved in 9,10-EpOME production. Because of the potential role of this enzyme in the development of neuropathy, inhibitors of this enzyme were used to target this pathway and the effects on sEPSC frequency and hypersensitivity to stimuli were assessed. In vivo, the administration of telmisartan and terfenadine significantly reduced 9,10-EpOME levels (p<0.05). These drugs also reduced mechanical and thermal hypersensitivity in mice (p<0.05).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Breast Cancerpaclitaxel
Previous Post

Correcting NAD+ depletion may improve muscular degeneration in Duchenne muscular dystrophy [PreClinical]

Next Post

Child maltreatment associated with poor adult socioeconomic status

RelatedReports

#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers
StudyGraphics

#VisualAbstract: Maintenance endocrine therapy plus bevacizumab after induction with paclitaxel is effective for ER+ breast cancers

August 2, 2022
#VisualAbstract: Metformin does not improve survival in patients with high-risk, nonmetastatic breast cancer
StudyGraphics

#VisualAbstract: Metformin does not improve survival in patients with high-risk, nonmetastatic breast cancer

July 26, 2022
#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage
StudyGraphics

#VisualAbstract: Concurrent use of tamoxifen with direct oral anticoagulants is not associated with an increased risk of hemorrhage

July 19, 2022
Choosing Wisely campaign releases recommendations in newborn medicine
Oncology

ERBB2-low tumours are not a distinct biologic or prognostic subgroup from ERBB2-0 tumour breast cancer.

July 11, 2022
Next Post
Child maltreatment associated with poor adult socioeconomic status

Child maltreatment associated with poor adult socioeconomic status

Type I diabetes not associated with early menopause [OVADIA study]

2 Minute Medicine Rewind December 19, 2016

High incidence of foreskin morbidity in uncircumcised males

Perioperative statin use may reduce complications and mortality in non-cardiac surgery

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Methamphetamine use associated with cardiovascular disease in hospitalized patients
  • Management of uncomplicated urinary tract infections amongst women in the United States Military Health System highly concordant with guidelines
  • Gout flares associated with a transient increase in subsequent risk of cardiovascular events
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.